UCB1244283 is a synaptic vesicle glycoprotein 2A ( SV2A ) allosteric modulator. UCB1244283 binds to a secondary ligand-binding site in SV2A and enhances orthosteric ligand engagement when the orthosteric site is occupied, by stabilizing the occluded state and slowing ligand dissociation. UCB1244283 shows a clear protective effect against both tonic and clonic convulsions in sound-sensitive mice. UCB1244283 can be used for epilepsy research [1] [2] [3].
References:
[1]. Pidathala S, et al. Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily. Nat Commun. 2025 Nov 28;16(1):10748.
[2]. Wood MD, et al. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2018 Sep;59(9):e147-e151.
[3]. Daniels V, et al. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013 Jul;169(5):1091-101.
References:
[1]. Pidathala S, et al. Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily. Nat Commun. 2025 Nov 28;16(1):10748.
[2]. Wood MD, et al. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2018 Sep;59(9):e147-e151.
[3]. Daniels V, et al. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013 Jul;169(5):1091-101.